Alvotech’s Research and Development is led by highly specialized teams working in our in-house R&D laboratories, which are equipped with a wide range of capabilities. Our platform across four development sites includes core competencies that drive the complete development of our biosimilar programs, from cell line development to regulatory filing.
Our Jülich based site comprises cell line development and process development laboratories, along with capabilities in physicochemical functional and bioanalytics to ensure that we develop a biosimilar product to the highest quality standards.
In Reykjavik, our research and development unit utilizes our state-of-the-art facility for formulation development and scale up to ensure seamless transfer of a process fit for commercial scale manufacturing.
Alvotech's intended acquisition of Glycothera, which is based in Hannover, Germany will further extend our capabilities in physicochemical characterization of our products.
Our Scientific Advisory Board, composed of key external experts with hands on experience in Biosimilar strategy and execution, acts as a sounding board to validate and guide our development strategies.
Our experienced and determined clinical development and regulatory affairs teams are allowing Alvotech to target a global, fast to filing approach.
Both the Clinical and Regulatory teams have great access to talent. Strong originator and biosimilar experience ensures fast and diligent execution of our clinical trials, guides our interaction with global regulatory agencies and drives filing of best in class dossiers.